Arvind Das, MD
Pulmonary Disease · Somerset, NJNPI 1770527756
Payments from drug & device makers
Across 192 payments — averaging $32.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$4K
- GSK$638
- Sanofi$261
- Harmony Biosciences LLC$194
- Jazz Pharmaceuticals Inc.$173
- Covidien LP$137
- plus $907 from 26 others
What the payments were for
- Food & beverage$5,75193%
- Education$4107%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 69 | $3,852 |
| GSK | 46 | $638 |
| Sanofi | 14 | $261 |
| Harmony Biosciences LLC | 7 | $194 |
| Jazz Pharmaceuticals Inc. | 8 | $173 |
| Covidien LP | 1 | $137 |
| Insmed, Inc. | 5 | $134 |
| Actelion Pharmaceuticals US, Inc. | 2 | $106 |
| Boehringer Ingelheim | 4 | $59 |
| Avadel CNS Pharmaceuticals, LLC | 3 | $57 |
| Inspire Medical Systems, Inc. | 2 | $47 |
| Sanofi-aventis U.S. LLC | 1 | $46 |
| Mylan Specialty L.p. | 3 | $41 |
| Merck | 3 | $41 |
| Amgen | 1 | $34 |
| Alk-abello, Inc | 2 | $31 |
| Regeneron Healthcare Solutions, Inc. | 2 | $31 |
| Mallinckrodt Hospital Products Inc. | 2 | $29 |
| Mallinckrodt Enterprises LLC | 2 | $27 |
| Gilead | 2 | $27 |
| Genentech USA, Inc. | 2 | $24 |
| Lilly USA, LLC | 1 | $18 |
| Greer Laboratories, Inc. | 1 | $17 |
| Novo Nordisk | 1 | $17 |
| Idorsia Pharmaceuticals US Inc | 1 | $17 |
| Paratek Pharmaceuticals, Inc. | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
| Eisai Inc. | 1 | $15 |
| Bristol Myers Squibb | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
| Axsome Therapeutics, Inc. | 1 | $14 |
| Circassia Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,161 in reported general payments places this provider in the 70th percentile of 472 pulmonary disease providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 305 | $243,836 |
| XywavSodium,calcium,mag,pot Oxybate | 12 | $230,598 |
| Fasenra PenBenralizumab | 24 | $136,633 |
| OfevNintedanib Esylate | 11 | $136,542 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 118 | $87,254 |
| NucalaMepolizumab | 19 | $67,814 |
| Breo ElliptaFluticasone/Vilanterol | 118 | $63,590 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 39 | $28,128 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 30 | $20,435 |
| Advair HfaFluticasone Propion/Salmeterol | 39 | $16,113 |
| Arnuity ElliptaFluticasone Furoate | 34 | $11,519 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 64 | $10,506 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 368 | $9,872 |
| EliquisApixaban | 15 | $8,972 |
| Incruse ElliptaUmeclidinium Bromide | 20 | $6,519 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Nucala, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta | $638 | $421,406535 claims |
| Boehringer IngelheimOfev, Stiolto Respimat | $59 | $156,97741 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $3,852 | $92,781135 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 472 pulmonary disease providers in New Jersey.
Other pulmonary disease in Somerset
- Lawrence DavanzoSomerset$26K
- Robin LucasSomerset$16K
- Reynold PanettieriNew Brunswick$2.5M
- Vinay SikandToms River$1.8M
- Stanley FielMorristown$1.3M
- Joseph HoffmanPark Ridge$1.1M
- Robert SussmanSummit$645K
- Ronaldo GoHackensack$563K
- Deborah GossHackensack$558K
- Sabina HussainNew Brunswick$555K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.